Medical Developments International Limited (MVP) Q4 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by and welcome to the Medical Developments International FY26 four-year results call. All participants are in a listen-only mode. If you wish to ask a question via the webcast, please enter it into the ask a question box and click submit. I would now like to hand the conference over to Mr. Frank McGregor, CEO. Please go ahead. Thank you very much. Good morning, everyone. Welcome to today's investor briefing. for our FY26 full year results. I am Brent McGregor. I'm the CEO and I'm joined today by Anita James, our Chief Financial Officer. So today I'm going to share with you an overview of our results and the company's key achievements in the year and take you through our priorities for FY27. Anita will speak to the financials in more detail, after which I will give some closing remarks. And then, as usual, we'll have plenty of time for questions at the end of the presentation. So, on that note, why don't we jump to slide four and walk you through the key messages we want to convey today. So, in short, our strategy to grow Pentarox, it continues to gain momentum. And as evidenced by our results in FY26, we made some great progress. We delivered a solid financial performance with very strong cash flow generation. And earnings in both our pain management in Penfrox and in our respiratory segments were materially improved. And in that regard, free cash flow landed at $4.2 million. So Penfrox in-market demand, it continues to grow. and it continues to grow across all of our jurisdictions. But we achieved some really significant milestones in AFY 26. A significant one in Europe was achieving the approval for the expansion of the PANFROC syndication to children from six years of age, where it was prior, it was 18 years of age. The most recent approval ...